Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 8/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 8/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 4/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | SQLE | Q14534 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314879 | 0.92 | — | — | |
| SCHEMBL10132045 | 0.87 | RAD52 (0.35) | SQLEGNAI3GNAO1GNAI1CXCR4 | |
| SCHEMBL16313544 | 0.83 | CARM1 (0.48) | CARM1PRMT6PRMT8PRMT1GNAI3 | |
| SCHEMBL3321877 | 0.82 | — | — | |
| SCHEMBL14508591 | 0.82 | RAD52 (0.44) | CARM1PRMT6PRMT8PRMT1CXCR4 | |
| SCHEMBL22431841 | 0.81 | EPHX2 (0.38) | CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL5348992 | 0.80 | RAD52 (0.47) | CXCR4RAD52SIGMAR1 | |
| SCHEMBL17715357 | 0.78 | KMT2A (0.45) | CARM1PRMT6PRMT8PRMT1SIGMAR1 | |
| SCHEMBL7013588 | 0.77 | — | — | |
| SCHEMBL18236766 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | CARM1 1650/4885PRMT6 2466/4885PRMT8 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.